🚀 VC round data is live in beta, check it out!
DBV Technologies Valuation Multiples
Discover revenue and EBITDA valuation multiples for DBV Technologies and similar public comparables like Zhejiang Ausun, Pharming, EyePoint, GuangYuYuan Chinese and more.
DBV Technologies Overview
About DBV Technologies
DBV Technologies SA is a clinical-stage specialty biopharmaceutical company focused on changing the field of immunotherapy by developing a novel technology platform called Viaskin. The therapeutic approach is based on epicutaneous immunotherapy or EPIT, its proprietary method of delivering biologically active compounds to the immune system through intact skin using Viaskin, an epicutaneous patch (i.e., a skin patch). Its main product candidate under development is Viaskin Peanut for the treatment of peanut-allergic patients. In addition, the company also has earlier-stage food allergy programs, including Viaskin Milk and Eosinophilic Esophagitis, or EoE.
Founded
2002
HQ
Employees
110
Website
Sectors
Financials (LTM)
EV
$1B
DBV Technologies Financials
DBV Technologies reported last 12-month revenue of $6M and negative EBITDA of ($143M).
In the same LTM period, DBV Technologies generated $6M in gross profit, ($143M) in EBITDA losses, and had net loss of ($150M).
Revenue (LTM)
DBV Technologies P&L
In the most recent fiscal year, DBV Technologies reported revenue of $6M and EBITDA of ($139M).
DBV Technologies expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue | $6M | XXX | $6M | XXX | XXX | XXX |
| Gross Profit | $6M | XXX | — | XXX | XXX | XXX |
| Gross Margin | 100% | XXX | — | XXX | XXX | XXX |
| EBITDA | ($143M) | XXX | ($139M) | XXX | XXX | XXX |
| EBITDA Margin | (2587%) | XXX | (2488%) | XXX | XXX | XXX |
| EBIT Margin | (2683%) | XXX | (2623%) | XXX | XXX | XXX |
| Net Profit | ($150M) | XXX | ($147M) | XXX | XXX | XXX |
| Net Margin | (2702%) | XXX | (2624%) | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
DBV Technologies Stock Performance
DBV Technologies has current market cap of $1B, and enterprise value of $1B.
Market Cap Evolution
DBV Technologies' stock price is $4.16.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $1B | $1B | -3.1% | XXX | XXX | XXX | $-0.50 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialDBV Technologies Valuation Multiples
DBV Technologies trades at 188.9x EV/Revenue multiple, and (7.3x) EV/EBITDA.
EV / Revenue (LTM)
DBV Technologies Financial Valuation Multiples
As of April 18, 2026, DBV Technologies has market cap of $1B and EV of $1B.
Equity research analysts estimate DBV Technologies' 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
DBV Technologies has a P/E ratio of (8.2x).
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $1B | XXX | $1B | XXX | XXX | XXX |
| EV (current) | $1B | XXX | $1B | XXX | XXX | XXX |
| EV/Revenue | 188.9x | XXX | 186.9x | XXX | XXX | XXX |
| EV/EBITDA | (7.3x) | XXX | (7.5x) | XXX | XXX | XXX |
| EV/EBIT | (7.0x) | XXX | (7.1x) | XXX | XXX | XXX |
| EV/Gross Profit | 188.9x | XXX | — | XXX | XXX | XXX |
| P/E | (8.2x) | XXX | (8.4x) | XXX | XXX | XXX |
| EV/FCF | (8.6x) | XXX | (8.6x) | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified DBV Technologies Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
DBV Technologies Margins & Growth Rates
DBV Technologies' revenue in the last 12 month grew by 628%.
DBV Technologies' revenue per employee in the last FY averaged $0.1M, while opex per employee averaged $1.3M for the same period.
DBV Technologies Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 628% | XXX | (4%) | XXX | XXX | XXX |
| EBITDA Margin | (2587%) | XXX | (2488%) | XXX | XXX | XXX |
| EBITDA Growth | (28%) | XXX | 7% | XXX | XXX | XXX |
| Revenue per Employee | — | XXX | $0.1M | XXX | XXX | XXX |
| Opex per Employee | — | XXX | $1.3M | XXX | XXX | XXX |
| S&M Expenses to Revenue | 74% | XXX | 57% | XXX | XXX | XXX |
| G&A Expenses to Revenue | 639% | XXX | 586% | XXX | XXX | XXX |
| R&D Expenses to Revenue | 2125% | XXX | 2084% | XXX | XXX | XXX |
| Opex to Revenue | — | XXX | 2626% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
DBV Technologies Public Comps
See public comps and valuation multiples for other Biopharmaceuticals comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| DBV Technologies | XXX | XXX | XXX | XXX | XXX | XXX |
| Zhejiang Ausun | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| EyePoint | XXX | XXX | XXX | XXX | XXX | XXX |
| GuangYuYuan Chinese | XXX | XXX | XXX | XXX | XXX | XXX |
| Guilin Sanjin | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
DBV Technologies M&A Activity
DBV Technologies acquired XXX companies to date.
Last acquisition by DBV Technologies was on XXXXXXXX, XXXXX. DBV Technologies acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by DBV Technologies
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialDBV Technologies Investment Activity
DBV Technologies invested in XXX companies to date.
DBV Technologies made its latest investment on XXXXXXXX, XXXXX. DBV Technologies invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by DBV Technologies
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout DBV Technologies
| When was DBV Technologies founded? | DBV Technologies was founded in 2002. |
| Where is DBV Technologies headquartered? | DBV Technologies is headquartered in France. |
| How many employees does DBV Technologies have? | As of today, DBV Technologies has over 110 employees. |
| Who is the CEO of DBV Technologies? | DBV Technologies' CEO is Daniel Tasse. |
| Is DBV Technologies publicly listed? | Yes, DBV Technologies is a public company listed on Euronext Paris. |
| What is the stock symbol of DBV Technologies? | DBV Technologies trades under DBV ticker. |
| When did DBV Technologies go public? | DBV Technologies went public in 2012. |
| Who are competitors of DBV Technologies? | DBV Technologies main competitors are Zhejiang Ausun, Pharming, EyePoint, GuangYuYuan Chinese. |
| What is the current market cap of DBV Technologies? | DBV Technologies' current market cap is $1B. |
| What is the current revenue of DBV Technologies? | DBV Technologies' last 12 months revenue is $6M. |
| What is the current revenue growth of DBV Technologies? | DBV Technologies revenue growth (NTM/LTM) is 628%. |
| What is the current EV/Revenue multiple of DBV Technologies? | Current revenue multiple of DBV Technologies is 188.9x. |
| Is DBV Technologies profitable? | No, DBV Technologies is not profitable. |
| What is the current EBITDA of DBV Technologies? | DBV Technologies has negative EBITDA and is not profitable. |
| What is DBV Technologies' EBITDA margin? | DBV Technologies' last 12 months EBITDA margin is (2587%). |
| What is the current EV/EBITDA multiple of DBV Technologies? | Current EBITDA multiple of DBV Technologies is (7.3x). |
| What is the current FCF of DBV Technologies? | DBV Technologies' last 12 months FCF is ($122M). |
| What is DBV Technologies' FCF margin? | DBV Technologies' last 12 months FCF margin is (2200%). |
| What is the current EV/FCF multiple of DBV Technologies? | Current FCF multiple of DBV Technologies is (8.6x). |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.